Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA [Yahoo! Finance]
Stoke Therapeutics, Inc. (STOK)
Last stoke therapeutics, inc. earnings: 11/12 08:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Lease is One of the Largest in Greater Boston Life Sciences Over the Past Year WALTHAM, Mass. Jan. 27, 2026 /PRNewswire/ -- Anchor Line Partners, LLC and Northwood Investors, LLC announced today that they have secured a significant long-term lease with biotechnology company Stoke Therapeutics (Nasdaq: STOK) at 245 Fifth Avenue in Waltham, Massachusetts. Stoke plans to relocate to its new 98,500 square-foot headquarters when the Company's current lease in Bedford, Massachusetts ends in late 2026. Stoke is dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development with Biogen as a first-in-class potential disease-modifying treatment for Dravet syndrome. Dravet syndrome is a severe neurodevelopmental disease that is characterized by recurrent seizures as well as significant cognitive and behavioral impairments. Stoke established its first headquarters in Bedford in 2015. Zorev
Show less
Read more
Impact Snapshot
Event Time:
STOK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STOK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STOK alerts
High impacting Stoke Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
STOK
News
- Stoke Therapeutics (NASDAQ:STOK) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.MarketBeat
- Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 [Yahoo! Finance]Yahoo! Finance
- Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026Business Wire
- Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MAPR Newswire
- Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business Wire
STOK
Earnings
- 11/4/25 - Miss
STOK
Sec Filings
- 2/5/26 - Form SCHEDULE
- 1/26/26 - Form 8-K
- 1/12/26 - Form 8-K
- STOK's page on the SEC website